In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry

The REG1 system consists of factor IXa inhibitor, RB006, an aptamer-based anticoagulant and its antidote, RB007. The optimal use of RB006 can be facilitated by understanding its effect on the formation of thrombin and fibrin, and other standard tests of coagulation. Blood from consented volunteers was drawn into 3.2% citrate (9:1 v/v) and either used immediately or centrifuged to obtain platelet-poor plasma. Increasing concentrations of aptamer (6-24 microg/ml) alone or in combination with heparin (0.1 U/ml) or lepirudin (0.2 microg/ml) were added to blood and plasma samples. Activated clotting times (ACT+, low range-ACT), thrombelastometry (ROTEM) or thrombelastography (TEG) were performed in recalcified whole blood samples. Thrombin generation, prothrombin time (PT) and activated partial thromboplastin time (aPTT) were performed in plasma samples. To some samples the antidote RB007 was added to neutralise the anticoagulation activity of RB006. In all experiment the ratio of RB006 to RB007 was kept 1:2. RB006 dose-dependently prolonged aPTT and low range-ACT, but, as expected, had no effect on PT. RB006 prolonged the lag time and decreased the peak of Actin-triggered thrombin generation. Thrombin-activated TEG demonstrated that RB006 decreases the rate of clot formation. These effects were potentiated when RB006 was combined with heparin or lepirudin. In all experiments RB007 reversed the effects of RB006 back to baseline. In conclusion, RB006 inhibits thrombin generation and clot formation in a concentration-dependent manner. It is feasible to monitor RB006 and its reversal with RB007 using aPTT, low range-ACT, and thrombin-activated TEG.

[1]  H. Hemker,et al.  Factor XI–Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. Oz,et al.  Selective Anticoagulation With Active Site Blocked Factor IXa in Synthetic Patch Vascular Repair Results in Decreased Blood Loss and Operative Time , 1997, ASAIO journal.

[3]  W. Funkhouser,et al.  In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. , 2007, Thrombosis research.

[4]  R. Colman,et al.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. , 1996, Circulation.

[5]  A. Gruber,et al.  Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. , 2003, Blood.

[6]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[7]  Kenichi A. Tanaka,et al.  Electron Microscopic Evaluations of Clot Morphology During Thrombelastography® , 2004, Anesthesia and analgesia.

[8]  C. Kempton,et al.  Antithrombin Affects Hemostatic Response to Recombinant Activated Factor VII in Factor VIII Deficient Plasma , 2008, Anesthesia and analgesia.

[9]  D. Tanné,et al.  Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. , 2008, Blood.

[10]  Kenichi A. Tanaka,et al.  Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[11]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[12]  J. Segal,et al.  Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence‐based review , 2005, Transfusion.

[13]  Subash C B Gopinath,et al.  A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway , 2006, Thrombosis and Haemostasis.

[14]  J. Weitz,et al.  New anticoagulants: beyond heparin, low‐molecular‐weight heparin and warfarin , 2005, British journal of pharmacology.

[15]  M. Carr,et al.  Monitoring coagulation and the clinical effects of recombinant factor VIIa. , 2004, Seminars in hematology.

[16]  M. Oz,et al.  Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. , 1998, The Journal of thoracic and cardiovascular surgery.

[17]  B. Sullenger,et al.  A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  K. Mann,et al.  Thrombin functions during tissue factor-induced blood coagulation. , 2002, Blood.

[19]  H. Philippou,et al.  Mechanisms of thrombin generation during surgery and cardiopulmonary bypass [see comments] , 1993 .

[20]  Kenichi A. Tanaka,et al.  Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven®) and Fibrinogen (Haemocomplettan® P) , 2008, Anesthesia and analgesia.

[21]  M. Oz,et al.  Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. , 1998, The Journal of thoracic and cardiovascular surgery.

[22]  T. Renné,et al.  Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis , 2006, The Journal of experimental medicine.

[23]  R. Becker,et al.  Factor IXa inhibitors as novel anticoagulants. , 2007, Arteriosclerosis, thrombosis, and vascular biology.